Neurocrine Biosciences (NBIX), a neuroscience-focused biopharmaceutical company, has been identified as a top value stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company features an attractive forward P/E ratio of 14.86, a Value Style Score of B, and has seen upward earnings estimate revisions with a consensus estimate of $9.09 per share for fiscal 2026, along with an average earnings surprise of +13.6%.

A comparison of two Medical-Drugs sector stocks reveals that Neurocrine Biosciences (NBIX) presents a better value opportunity than Sandoz Group AG (SDZNY). Both stocks hold a Zacks Rank #2 (Buy) with positive earnings outlooks, but NBIX's superior valuation metrics—including a lower forward P/E ratio of 15.55 versus SDZNY's 20.49, and a PEG ratio of 0.53 compared to 1.69—earned it a Value grade of B versus SDZNY's C grade.

Neurocrine Biosciences (NBIX), a neuroscience-focused biopharmaceutical company, has been identified as a top growth stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company is forecasting year-over-year earnings growth of 42.3% for fiscal 2026, with a consensus earnings estimate of $9.09 per share and an average earnings surprise of +13.6%.

Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders.

Neurocrine Biosciences has received FDA IND acceptance for a Phase 2 study of NBI-1117567, an oral muscarinic M1/M4 selective agonist for Alzheimer's cognition. Nxera Pharma will receive a $10 million milestone payment. This marks the third compound in Nxera's muscarinic agonist portfolio to advance to Phase 2, following direclidine in Phase 3 and NBI-1117570 in Phase 2.

Nxera Pharma reported strong Q2 2026 results with revenue of JPY 18.9 billion, up from the prior year, driven by eight R&D milestone events. The company achieved key regulatory designations for vamorolone in South Korea, progressed partnered programs with Neurocrine, Lilly, and AbbVie, and benefited from Lilly's acquisition of Centessa Pharmaceuticals. Operating profit turned positive at JPY 1.9 billion versus a prior loss, with core operating profit reaching JPY 6.5 billion.

Fundstrat Capital completed its May 2026 quarterly rebalance of the Fundstrat Granny Shots US Small- & Mid-Cap ETF (GRNJ), adding 10 stocks including First Solar, Zoom, Credo Technology, and Neurocrine Biosciences, while removing 8 positions. CIO Tom Lee positions the portfolio for a 'challenging but ultimately constructive' environment, with the strategy focusing on companies benefiting from structural tailwinds across themes like Millennials, Global Labor Supply, Energy, Cybersecurity, and Easing Financial Conditions.

Nxera Pharma reported strong Q1 2026 results with revenue of JPY 11.3 billion, a significant increase from the prior year, driven by seven R&D milestone events. The company signed a licensing agreement with Santhera for vamorolone in APAC markets, achieved positive Phase 3 results for daridorexant in South Korea, and received milestone payments from Neurocrine and AbbVie. Additionally, Centessa Pharmaceuticals (spun out from Nxera in 2019) agreed to be acquired by Eli Lilly for up to $7.8 billion, with Nxera retaining rights to milestone and royalty payments.

Neurocrine Biosciences has initiated a Phase 2 clinical trial of NBI-1117570, a dual muscarinic M1/M4 receptor agonist discovered by Nxera Pharma, for treating schizophrenia. Nxera will receive $22.5 million in milestone payments from Neurocrine as a result of this achievement.

Soleno Therapeutics agreed to be acquired by peer Neurocrine Biosciences for $2.9 billion, or $53 per share in an all-cash deal, representing a 34% premium. The acquisition is driven by Soleno's FDA-approved drug Vykat XR for treating hyperphagia in Prader-Willi Syndrome patients. Soleno's stock surged 32% on the announcement, and the deal is expected to close within 90 days.

Neurocrine Biosciences announced its acquisition of Soleno Therapeutics for $2.9 billion ($53 per share in cash) to expand its rare disease portfolio with Vykat XR, an FDA-approved treatment for hyperphagia in Prader-Willi syndrome. The deal is expected to close within 90 days. Vykat XR generated $190 million in revenue in 2025, demonstrating strong market adoption despite earlier criticism from a short report.

Sarissa Capital Management established a new $5.79 million position in clinical-stage biotech Biohaven, acquiring 513,184 shares during Q4 2025. Despite the stock falling 70% over the past year due to FDA rejection of troriluzole and disappointing trial results, the fund's investment signals potential turnaround prospects. Biohaven has refocused on late-stage programs including a degrader platform and Phase 2 obesity candidate with data expected in H2 2026, while maintaining a strengthened balance sheet with $500.9 million in cash.